Main menu

NEW YORK (GenomeWeb) – Bio-Techne announced today that it has agreed to acquire Advanced Cell Diagnostics for $250 million in cash, plus an additional consideration of $75 million if certain milestones are achieved.

The deal is expected to close on or about August 1, and will be financed through a combination of cash on hand and a revolving line of credit facility that Bio-Techne said it expects to obtain. The company expects the acquisition to be slightly dilutive to its adjusted earnings per share for fiscal year 2017, and accretive thereafter.